Mutation detail:
| Mutation site | R151K |
| Virus | Human respiratory syncytial virus |
Mutation level  |
Amino acid Level |
| Gene/protein/region type | M2 |
| Gene ID | 1494476 |
| Country | - |
| Mutation type |
nonsynonymous mutation |
| Genotype/subtype/clade | A |
| Sample |
cell line |
| Variants | - |
| Viral reference sequence | AY911262.1 |
| Drug/antibody/vaccine | Cyclopamine-resistant |
| Transmissibility |
- |
| Transmission mechanism | - |
| Pathogenicity |
- |
| Pathogenicity mechanism | - |
| Immune escape mutation | - |
| Immune escape mechanism | - |
| RT-PCR primers probes | - |
Protein detail:
| Protein name | Matrix (M2/22K) |
| Uniprot protein ID | P04545 |
| Protein length | 194 amino acids |
| Protein description | Matrix (M2/22K) acts as a tetrameric transcription processivity factor that binds in a competitive manner to RNA and the phosphoprotein (P) to prevent premature termination during transcription. Transcription anti-terminator that enhances readthrough of intergenic junctions during viral transcription. Preferentially binds to poly(A)-rich sequences. Matrix (M2/22K) plays a role in the association of the matrix protein with the nucleocapsid, which initiates assembly and budding. Also, can activate host NF kappa-B through association with host RELA. |
Literature information:
| Pubmed ID | 27194388 |
| Clinical information | No |
| Disease | - |
| Published year | 2016 |
| Journal | Scientific reportS |
| Title | Targeting human respiratory syncytial virus transcription anti-termination factor M2-1 to inhibit in vivo viral replication |
| Author | B. Bailly,C.-A. Richard,G. Sharma,L. Wang,L. Johansen |
| Evidence | Genome sequencing and alignment of the supernatants revealed three coding mutations located in the hRSV M2-1 gene (Fig. 3c). While WTp was found to be identical to the original hRSV sequence, CPMR-1 and CPMR-2 consisted of a mixed population of wild-type |